Thursday, December 28, 2017 10:15 PM ET
BeiGene (BGNE) Insider Makes Significant Share Sale
There was a significant sale of shares of BeiGene by an insider today, as indicated in a form 4 document filed with the SEC. One insider — John Oyler, 10% Owner, Director and Officer — disposed of 20,137 shares in the company having a market value of approximately $1,942,515. There have been 3 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the disposition of 387,164 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 407,301 shares and have averaged 101,825 shares per transaction over this time period.
The number of insider buy/sell trades at BeiGene is above that of the 279 peer company average over the last 90-day period. The Bio Therapeutic Drugs peer group saw 315 buy/sell trades during this period for an average of 1.1 transactions per company. However, the number of shares traded per transaction by BeiGene insiders is lower than its peers. Within the peer group there were 43,760,863 shares purchased and 36,122,656 shares sold with company insiders purchasing 37,079 shares on average over this time period.
Insider buying and selling activity that is significant has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in creating and writing this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2017 UpTick Data Technologies. All rights reserved.